Key Drivers
- Margin Expansion
- Debt Reduction
- Intangible Exposure
AIAI Summary
UFPT's pivot into acquisition-led medical-device manufacturing expands its growth runway, but at ~30–33x earnings the investment case now hinges on CI Medical integration, margin accretion, and sustained 12%–18% growth—making a pullback attractive only if cash conversion and deal economics remain intact.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Debt Reduction
- •Intangible Exposure
UFPT shows strong profitability, liquidity, free cash flow, and declining leverage, but elevated valuation, lower cash reserves, and high intangible assets warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Oversold momentum
- •Support holding
UFPT remains bearish over the last month below its $289.88 average, but oversold conditions and $275 support may allow a tactical bounce; consider improvement only above $281–$289.
Price stabilized near $275–$278 after a 9.1% last-month decline
Sentiment & News
Key News Insights:
- •Growth Target
- •M&A Pipeline
- •Institutional Buying
UFPT's 12%–18% growth target, medical-device M&A pipeline, and rising institutional interest signal constructive momentum despite insider selling and elevated options volatility.
The developments are broadly positive for UFPT, though volatility and execution risks warrant monitoring
Similar Companies in Healthcare
Other companies in the same sector with AI ratings